Ocular Therapeutix/$OCUL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ocular Therapeutix
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
- Ticker
- $OCUL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 325
- Headquarters
- Bedford, United States
- Website
- www.ocutx.com
OCUL Metrics
BasicAdvanced
$1.5B
-
-$1.41
0.97
-
Price and volume
Market cap
$1.5B
Beta
0.97
52-week high
$16.44
52-week low
$6.23
Average daily volume
3.4M
Financial strength
Current ratio
13.105
Quick ratio
12.789
Long term debt to equity
0.147
Total debt to equity
0.153
Interest coverage (TTM)
-27.53%
Profitability
EBITDA (TTM)
-308.458
Gross margin (TTM)
-342.26%
Net profit margin (TTM)
-579.09%
Operating margin (TTM)
-603.03%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-34.95%
Return on equity (TTM)
-72.99%
Valuation
Price to revenue (TTM)
28.243
Price to book
2.9
Price to tangible book (TTM)
2.9
Price to free cash flow (TTM)
-5.763
Free cash flow yield (TTM)
-17.35%
Free cash flow per share (TTM)
-1.192
Growth
Revenue change (TTM)
-8.13%
Earnings per share change (TTM)
10.45%
3-year revenue growth (CAGR)
-1.58%
10-year revenue growth (CAGR)
40.28%
3-year earnings per share growth (CAGR)
5.63%
10-year earnings per share growth (CAGR)
-2.36%
What the Analysts think about OCUL
Analyst ratings (Buy, Hold, Sell) for Ocular Therapeutix stock.
Analyst projections of the future price of Ocular Therapeutix stock.
Bulls say / Bears say
In the Phase 3 SOL-1 trial, AXPAXLI beat aflibercept on vision maintenance: 74.1% of treated patients maintained vision at week 36 versus 56.6%, and 65.9% did so at week 52 versus 44.8%. (GlobeNewswire)
The FDA’s September pre-NDA meeting confirmed alignment on the content and format of the planned application, and Ocular remains on track to file in Q4 2026. The 505(b)(2) route could also shorten review by up to 60 days. (GlobeNewswire)
SOL-1 analyses suggest AXPAXLI could cut injection burden by up to 72% over 60 weeks compared with projected every-eight-week aflibercept dosing. Fewer injections could make treatment more manageable for patients and clinicians if the benefit translates into practice. (GlobeNewswire)
FDA alignment clears a path to submit, but it does not assure approval: the application is planned around one pivotal efficacy trial plus confirmatory evidence, and the agency must still judge whether the full package supports approval. (Retinal Physician)
Ocular has pushed SOL-R’s efficacy results to the first quarter of 2028 while keeping the trial masked, and those results are no longer expected to support the planned US application. That delays an important additional efficacy readout and leaves the near-term case more dependent on SOL-1. (GlobeNewswire)
The current business generates little cushion against development costs: second-quarter revenue was $13.5 million, essentially flat year on year, while the net loss was $78.8 million. This leaves the investment case heavily reliant on AXPAXLI’s regulatory and commercial execution. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2026.
OCUL Financial Performance
Revenues and expenses
OCUL Earnings Performance
Company profitability
Upcoming events
No upcoming events
OCUL News
AllArticlesVideos
Funds containing OCUL
AllUSDGBPEUR
Fund name | Fund size | $OCUL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.11% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.11% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.